An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.
Ontology highlight
ABSTRACT: Pulmonary arterial hypertension (PAH), also known as Group 1 Pulmonary Hypertension (PH), is a PH subset characterized by pulmonary vascular remodeling and pulmonary arterial obstruction. PAH has an estimated incidence of 15-50 people per million in the United States and Europe, and is associated with high mortality and morbidity, with patients' survival time after diagnosis being only 2.8 years. According to current guidelines, right heart catheterization is the gold standard for diagnostic and prognostic evaluation of PAH patients. However, this technique is highly invasive, so it is not used in routine clinical practice or patient follow-up. Thereby, it is essential to find new non-invasive strategies for evaluating disease progression. Biomarkers can be an effective solution for determ
SUBMITTER: Santos-Gomes J
PROVIDER: S-EPMC9333554 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA